Bristol Myers Squibb Company $BMY Stake Decreased by Roman Butler Fullerton & Co.

Posted by Stanley Muller on Oct 28th, 2026

Roman Butler Fullerton & Co. cut its position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 46.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,516 shares of the biopharmaceutical company’s stock after selling 12,673 shares during the quarter. Roman Butler Fullerton & Co.’s holdings in Bristol Myers Squibb were worth $854,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BMY. Primecap Management Co. CA bought a new stake in shares of Bristol Myers Squibb during the second quarter valued at approximately $1,436,115,000. Legal & General Group Plc bought a new position in Bristol Myers Squibb in the second quarter worth $980,862,000. BlackRock Inc. lifted its position in Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after purchasing an additional 8,702,106 shares during the period. State Street Corp boosted its stake in Bristol Myers Squibb by 7.3% during the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after buying an additional 7,192,724 shares in the last quarter. Finally, Caisse de depot et placement du Quebec acquired a new stake in Bristol Myers Squibb during the second quarter worth $243,646,000. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Encouraging cancer-drug data strengthens the growth pipeline. Izalontamab brengitecan (Iza-Bren) reportedly doubled median progression-free survival versus chemotherapy in previously treated EGFR-mutated non-small-cell lung cancer. Separate Phase 3 data indicated the drug reduced breast-cancer progression risk by as much as 38%. The results could support a future growth driver as Bristol Myers Squibb manages declines from older products. Iza-Bren lung cancer trial results
Positive Sentiment: Valuation remains supportive. One analysis argues that BMY still trades below fair value based on expected future cash generation, despite its strong 12-month advance. Analysts also point to growth medicines and higher Eliquis guidance as potential offsets to legacy-portfolio weakness. BMY valuation analysis
Neutral Sentiment: Third-quarter earnings are the next major catalyst. Preview coverage is focused on revenue trends, Eliquis performance, newer growth products and the pace of decline in older drugs. The market is waiting to see whether operating results support the company’s full-year EPS guidance of $6.75–$7.00. Q3 earnings preview
Neutral Sentiment: Analyst sentiment is cautious but not bearish. Piper Sandler lowered its price target from $82 to $78 while retaining an Overweight rating, implying further upside. Zacks Research maintains a Hold rating and trimmed its Q3 2027, FY2027 and FY2028 EPS estimates only slightly, to $1.55, $6.23 and $5.21, respectively. Piper Sandler BMY target
Negative Sentiment: Patent expirations remain the principal risk. Declining sales from key legacy medicines could pressure earnings, and estimates already imply lower profitability in later years. Investors must weigh the pipeline’s commercialization potential against this erosion. BMY bargain or value trap analysis

Insiders Place Their Bets

In other news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.05% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of recent research reports. Morgan Stanley restated an “underweight” rating and issued a $41.00 price objective (up from $40.00) on shares of Bristol Myers Squibb in a research note on Wednesday, October 7th. Roth Capital assumed coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “buy” rating and a $75.00 target price on the stock. Rothschild & Co Redburn lifted their target price on shares of Bristol Myers Squibb from $51.00 to $53.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. Zacks Research cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 22nd. Finally, Bank of America dropped their price target on shares of Bristol Myers Squibb from $71.00 to $66.00 in a research report on Friday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $65.50.

Read Our Latest Analysis on Bristol Myers Squibb

Bristol Myers Squibb Trading Up 0.0%

Shares of NYSE:BMY opened at $61.63 on Wednesday. The business’s fifty day moving average price is $63.09 and its two-hundred day moving average price is $59.85. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter in the prior year, the company earned $1.46 earnings per share. The business’s revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.51 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be given a $0.63 dividend. The ex-dividend date is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%.

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.